Orphan Drugs Partnering Terms and Agreements -- NEW YORK, Aug. 8, 2013 /PRNewswire/ -- Orphan Drugs Partnering Terms and Agreements http://www.reportlinker.com/p01098515/Orphan-Drugs-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication The Orphan Drugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in orphan drugs partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Orphan drugs partnering contract documents Top orphan drugs deals by value The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 140 links to online copies of actual orphan drugs deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of orphan drugs dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details of disclosed headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading orphan drugs deals since 2007. Deals are listed by headline value, signed by bigp harma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of orphan drugs deals, as well as contract documents available in the public domain. Chapter 6 and 7 provides a comprehensive and detailed review of orphan drugs partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007. In addition, a comprehensive appendix is provided organized by orphan drugs partnering company A-Z , deal type definitions and orphan drugs partnering agreements example. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan drugs technologies and products. Report scope Orphan Drugs Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to orphan drugs trends and structure of deals entered into by leading companies worldwide. Orphan Drugs Partnering Terms and Agreements includes: Trends in orphan drugs dealmaking in the biopharma industry since 2007 Analysis of orphan drugs deal structure Access to headline, upfront, milestone and royalty data Access to 140 orphan drugs deal records The leading orphan drugs deals by value since 2007 In Orphan Drugs Partnering Terms and Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target The Ophan Drugs Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 140 orphan drugs deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How aresales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Orphan Drugs Partnering Terms and Agreements provides the reader with the following key benefits: In-depth understanding of orphan drugs deal trends since 2007 Access to headline, upfront, milestone and royalty data Acces to the structure of orphan drugs agreements with numerous real life case studies Comprehensive access to over 140 actual orphan drugs deals entered into by the world's biopharma companies Insight into the terms included in a orphan drugs agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in orphan drugs dealmaking 2.1. Introduction 2.2. Orphan drugs partnering over the years 2.3. Bigpharma orphan drugs dealmaking activity 2.4. Big biotech orphan drugs dealmaking activity 2.5 Most active orphan drugs dealmakers 2.6. Orphan drugs partnering by deal type 2.7. Orphan drugs partnering by industry sector type 2.8. Orphan drugs partnering by stage of development 2.9. Orphan drugs partnering by therapy area 2.10. Orphan drugs partnering by orphan drug technology type 2.11. Average deal terms for orphan drugs partnering 2.11.1 Orphan drugs headline values 2.11.2 Orphan drugs upfront payments 2.11.3 Orphan drugs milestone payments 2.11.4 Orphan drugs royalty rates 2.12. The anatomy of orphan drug partnering 2.12.a. Case study 1: Xoma, Servier- January 2011 2.12.b. Case study 2: Epicept, Meda: January 2010 Chapter 3 - Leading orphan drugs deals 3.1. Introduction 3.2. Top orphan drugs deals by value 3.3. Top orphan drugs deals involving big pharma or big biotech Chapter 4 - Bigpharma orphan drugs deals 4.1. Introduction 4.2. How to use bigpharma partnering deals 4.3. Big pharma orphan drugs partnering company profiles Chapter 5 - Bigbiotech orphan drugs deals 5.1. Introduction 5.2. How to use bigbiotech partnering deals 5.3. Bigbiotech orphan drugs partnering company profiles Chapter 6 - Orphan Drugs Dealmaking directory 6.1. Introduction 6.2. Company A-Z 6.3. By deal type Asset purchase Bigpharma outlicensing Co-development Collaborative R&D Co-market Contract service Co-promotion Development Distribution Equity purchase Grant Joint venture Licensing Manufacturing Manufacturing - OEM Marketing Option Promotion Research Settlement Supply Technology transfer 6.4. By industry sector Academic Bigbiotech Bigpharma Biotech Drug delivery Diagnostic Financial Government Non-profit Pharmaceutical Research tools Services Specialty pharma 6.5. By stage of development Discovery Formulation Marketed Regulatory Phase I Phase II Phase III Preclinical 6.6. By therapy area Cardiovascular Central Nervous System Dental Dermatology Gastrointestinal Genetic disorders Genitourinary Hematology Hospital care Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Pediatrics Psychiatry Respiratory Chapter 7 - Dealmaking by orphan drugs technology type 7.1. Introduction 7.2. Deals by orphan drugs type Chapter 8 - Partnering resource center 8.1. Online partnering 8.2. Partnering events 8.3. Further reading on dealmaking Appendices Appendix 1 - Deal type definitions About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form - Reports Table of figures To order this report: Drug_and_Medication Industry: Orphan Drugs Partnering Terms and Agreements